Thomas Yau Selected Research

Thomas Yau Research Topics

Disease

51	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 01/2007
30	Neoplasms (Cancer) 09/2022 - 01/2007
7	Disease Progression 01/2022 - 01/2006
6	Breast Neoplasms (Breast Cancer) 09/2022 - 01/2006
6	Neoplasm Metastasis (Metastasis) 01/2019 - 11/2008
5	Colorectal Neoplasms (Colorectal Cancer) 07/2017 - 04/2009
4	Hepatitis B 11/2020 - 01/2009
3	Hypertension (High Blood Pressure) 01/2022 - 07/2021
3	Fibrosis (Cirrhosis) 01/2021 - 11/2012
3	Liver Neoplasms (Liver Cancer) 12/2020 - 11/2008
3	Diarrhea 01/2020 - 02/2013
2	Cholangiocarcinoma 01/2022 - 04/2014
2	Inflammation (Inflammations) 01/2022 - 12/2020
2	Hepatitis 01/2022 - 06/2017
2	Nausea 12/2019 - 02/2013
2	Thrombocytopenia (Thrombopenia) 01/2019 - 12/2013
2	Infections 01/2019 - 06/2017
2	Colonic Neoplasms (Colon Cancer) 11/2013 - 11/2012
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 03/2013 - 03/2010
2	Stomach Neoplasms (Stomach Cancer) 01/2013 - 01/2012
2	Carcinogenesis 01/2012 - 01/2009
2	Hemangiosarcoma (Angiosarcoma) 06/2011 - 04/2008
2	Thrombosis (Thrombus) 01/2009 - 11/2008
1	Injection Site Reaction 09/2022
1	Back Pain (Backache) 05/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2022
1	Breakthrough Infections 01/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Chemical and Drug Induced Liver Injury 01/2022
1	Hepatic Encephalopathy 01/2022
1	Multiple Organ Failure (MODS) 01/2022
1	Tumor Lysis Syndrome 01/2022
1	Varicose Veins (Varicose Vein) 01/2022
1	Cardiotoxicity 12/2021
1	Triple Negative Breast Neoplasms 12/2021
1	Central Nervous System Diseases (CNS Diseases) 01/2020

Drug/Important Bio-Agent (IBA)

25	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 01/2009
8	Biomarkers (Surrogate Marker)IBA 06/2022 - 01/2012
8	NivolumabIBA 01/2022 - 06/2017
6	Bevacizumab (Avastin)FDA Link 01/2022 - 01/2009
6	cabozantinibIBA 01/2022 - 01/2020
6	pembrolizumabIBA 01/2022 - 01/2020
5	Trastuzumab (Herceptin)FDA Link 09/2022 - 01/2006
4	Immune Checkpoint InhibitorsIBA 01/2022 - 06/2017
4	atezolizumabIBA 01/2022 - 07/2020
4	Tyrosine Kinase InhibitorsIBA 10/2021 - 01/2019
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2007
3	Capecitabine (Xeloda)FDA Link 01/2022 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 09/2021 - 11/2008
3	IpilimumabIBA 06/2021 - 11/2020
3	Pharmaceutical PreparationsIBA 12/2019 - 02/2013
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 01/2014
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 01/2022
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 04/2008
2	neratinibIBA 10/2021 - 01/2020
2	LigandsIBA 09/2021 - 01/2021
2	B7-H1 AntigenIBA 09/2021 - 09/2021
2	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020 - 11/2010
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2020 - 01/2011
2	regorafenibIBA 01/2020 - 07/2017
2	Antiviral Agents (Antivirals)IBA 06/2017 - 03/2015
2	Cetuximab (Erbitux)FDA Link 01/2017 - 11/2013
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2016 - 04/2015
2	ArginaseIBA 04/2015 - 02/2013
2	Leucovorin (Folinic Acid)FDA Link 01/2014 - 04/2009
2	Fluorouracil (Carac)FDA LinkGeneric 01/2014 - 04/2009
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2013 - 12/2012
2	NeuropeptidesIBA 03/2013 - 03/2010
1	pertuzumabIBA 09/2022
1	spartalizumabIBA 06/2022
1	roblitinibIBA 06/2022
1	Antirheumatic Agents (DMARD)IBA 05/2022
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022
1	Alanine Transaminase (SGPT)IBA 01/2022
1	AntibodiesIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2021
1	AnthracyclinesIBA 12/2021
1	Epirubicin (Ellence)FDA LinkGeneric 12/2021
1	taxaneIBA 12/2021
1	Docetaxel (Taxotere)FDA Link 12/2021
1	AntigensIBA 01/2021
1	tremelimumabIBA 01/2021
1	durvalumabIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Phosphotransferases (Kinase)IBA 09/2020
1	EpitopesIBA 01/2020

Therapy/Procedure

28	Therapeutics 05/2022 - 11/2008
10	Drug Therapy (Chemotherapy) 09/2022 - 04/2008
2	Immunotherapy 01/2022 - 01/2021
2	Neoadjuvant Therapy 12/2021 - 03/2019
2	Liver Transplantation 01/2021 - 02/2013
2	Hepatectomy 01/2014 - 11/2013
2	Molecular Targeted Therapy 01/2013 - 09/2010
2	Adjuvant Chemotherapy 04/2010 - 04/2009
2	Radiotherapy 09/2008 - 10/2003
1	Drug Tapering 12/2021